Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors

Table 1

Patient characteristic.

Variable	Number of patients	%
Patient number	110	100
Gender
Male	100	90.9
Female	10	9.1
Age (year) median (range)	54.5 (31-84)
ECOG performance score
0-1	78	70.9
≥2	32	29.1
Child-Pugh class
A	98	89.1
B	12	10.9
BMI
<25	80	72.7
≥25	30	27.3
Viral hepatitis
HBV	110	100
BCLC stage
B	18	16.4
C	92	83.6
CNLC stage
IIb	18	16.4
IIIa	23	20.9
IIIb	69	62.7
Treatment of primary tumor
TACE	87	79.1
RFA	15	13.6
RT	25	22,7
Resection of liver cancer	33	30
None	15	13.6
The cycles of anti-PD-1 therapy
Two cycles	55	50.0
More than three cycles	55	50.0
PVTT
Yes	65	59.1
None	45	40.9
AFP level
<400 ng/ml	49	44.5
≥400 ng/ml	61	55.5
Lymphocyte 10^9/LMedian (range)	1.233 (0.18-4.09)
Neutrophil 10^9/L median (range)	3.339 (0.97-10.53)
Monocyte 10^9/L median (range)	0.46 (0.13-1.38)
Platelet 10^9/L median (range)	141.67 (27-496)
SII
<970	99	90.0
≥970	11	10.0
PLR
<140	69	62.7
≥140	41	37.3
NLR
<5	89	80.9
≥5	21	19.1
LMR
<1.8	31	28.2
≥1.8	79	71.8